APA (7th ed.) Citation

AE, B., B, P., M, H., A, K., R, C., U, K., & M, S. (2004). Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer chemotherapy and pharmacology, 53(2), 102. https://doi.org/10.1007/s00280-003-0722-9

Chicago Style (17th ed.) Citation

AE, Bolton, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, and Seiberling M. "Effect of Rifampicin on the Pharmacokinetics of Imatinib Mesylate (Gleevec, STI571) in Healthy Subjects." Cancer Chemotherapy and Pharmacology 53, no. 2 (2004): 102. https://doi.org/10.1007/s00280-003-0722-9.

MLA (9th ed.) Citation

AE, Bolton, et al. "Effect of Rifampicin on the Pharmacokinetics of Imatinib Mesylate (Gleevec, STI571) in Healthy Subjects." Cancer Chemotherapy and Pharmacology, vol. 53, no. 2, 2004, p. 102, https://doi.org/10.1007/s00280-003-0722-9.